Keyphrases
Lung Cancer
100%
5-hydroxymethylcytosine (5hmC)
100%
Cell-free DNA (cfDNA)
100%
Immunotherapy Response
100%
Confidence Interval
75%
Predictive Score
50%
Immune Checkpoint Inhibitor Treatment
50%
Immune Checkpoint Inhibitors
25%
Treatment Response
25%
Hazard Ratio
25%
Progression-free Survival
25%
Validation Set
25%
DNA Samples
12%
Patient Response
12%
Tumor
12%
Signaling Pathway
12%
Therapeutic Outcome
12%
Associated Genes
12%
Treatment Response Prediction
12%
Objective Response Rate
12%
Lung Cancer Patients
12%
Predictive Models
12%
Genomic Profiling
12%
Plasma Cell-free DNA
12%
Test Validity
12%
Predictive Ability
12%
Long Progression-free Survival
12%
Control Sets
12%
Gene Pathway
12%
Programmed Death-ligand 1 (PD-L1)
12%
Robust Biomarker
12%
Predictive Signature
12%
Medicine and Dentistry
Immunotherapy
100%
Lung Cancer
100%
Cell-Free DNA
100%
5 Hydroxymethylcytosine
100%
Immune Checkpoint Inhibitor
75%
Treatment Response
37%
Progression Free Survival
37%
Hazard Ratio
25%
Neoplasm
12%
Cell Signaling Pathway
12%
Biological Marker
12%
Programmed Death 1 Ligand 1
12%
Median Test
12%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Immunotherapy
100%
5 Hydroxymethylcytosine
100%
Immune Checkpoint Inhibitor
75%
Progression Free Survival
37%
Neoplasm
12%
Biological Marker
12%
Programmed Death 1 Ligand 1
12%
Biochemistry, Genetics and Molecular Biology
5-Hydroxymethylcytosine
100%
Immune Checkpoints
75%
Progression Free Survival
37%
Immunoglobulin Producing Cell
12%